Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

February 01, 1996; Volume 49,Issue 2
  • You have access
    RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
    A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
    Molecular Pharmacology February 1996, 49 (2) 209-215;
  • You have access
    The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
    K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer
    Molecular Pharmacology February 1996, 49 (2) 216-223;
  • You have access
    Expression cloning of a human brain neuropeptide Y Y2 receptor.
    D R Gehlert, L S Beavers, D Johnson, S L Gackenheimer, D A Schober and R A Gadski
    Molecular Pharmacology February 1996, 49 (2) 224-228;
  • You have access
    Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides.
    M D Hollenberg, M Saifeddine and B al-Ani
    Molecular Pharmacology February 1996, 49 (2) 229-233;
  • You have access
    Epitope mapping studies with human anti-cytochrome P450 3A antibodies.
    J S Leeder, A Gaedigk, X Lu and V A Cook
    Molecular Pharmacology February 1996, 49 (2) 234-243;
  • You have access
    Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
    J M Rusnak, T P Calmels, D G Hoyt, Y Kondo, J C Yalowich and J S Lazo
    Molecular Pharmacology February 1996, 49 (2) 244-252;
  • You have access
    Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
    K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting
    Molecular Pharmacology February 1996, 49 (2) 253-259;
  • You have access
    Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes.
    S P Carpenter, J M Lasker and J L Raucy
    Molecular Pharmacology February 1996, 49 (2) 260-268;
  • You have access
    Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
    Z Wang and B K Sinha
    Molecular Pharmacology February 1996, 49 (2) 269-275;
  • You have access
    Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
    S J Webb, G H Xiao, T E Geoghegan and R A Prough
    Molecular Pharmacology February 1996, 49 (2) 276-287;
  • You have access
    Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance.
    X Zhang and C D Smith
    Molecular Pharmacology February 1996, 49 (2) 288-294;
  • You have access
    Effects of expression of a mouse brain L-type calcium channel alpha 1 subunit on secretion from bovine adrenal chromaffin cells.
    P F Wick, R E Westenbroek and R W Holz
    Molecular Pharmacology February 1996, 49 (2) 295-302;
  • You have access
    Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration.
    J L Venero, F Hefti and B Knusel
    Molecular Pharmacology February 1996, 49 (2) 303-310;
  • You have access
    Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
    E G Schuetz, W T Beck and J D Schuetz
    Molecular Pharmacology February 1996, 49 (2) 311-318;
  • You have access
    Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
    J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
    Molecular Pharmacology February 1996, 49 (2) 319-328;
  • You have access
    Oct-1 transcription factor is a negative regulator of rat CYP1A1 expression via an octamer sequence in its negative regulatory element.
    K Sterling and E Bresnick
    Molecular Pharmacology February 1996, 49 (2) 329-337;
  • You have access
    Reserpine inhibits amphetamine action in ventral midbrain culture.
    D Sulzer, C St Remy and S Rayport
    Molecular Pharmacology February 1996, 49 (2) 338-342;
  • You have access
    The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    B Rene, P Fosse, T Khelifa, A Jacquemin-Sablon and C Bailly
    Molecular Pharmacology February 1996, 49 (2) 343-350;
  • You have access
    Intracellular trafficking of the muscarinic acetylcholine receptor: importance of subtype and cell type.
    J A Koenig and J M Edwardson
    Molecular Pharmacology February 1996, 49 (2) 351-359;
  • You have access
    Stimulation of Ca(2+)-dependent membrane currents in Xenopus oocytes by microinjection of pyrimidine nucleotide-glucose conjugates.
    H Y Kim, D Thomas and M R Hanley
    Molecular Pharmacology February 1996, 49 (2) 360-364;
  • You have access
    Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization.
    E Hermans, J N Octave and J M Maloteaux
    Molecular Pharmacology February 1996, 49 (2) 365-372;
  • You have access
    Dopamine D2L receptors stimulate Na+/K(+)-ATPase activity in murine LTK- cells.
    I Yamaguchi, S F Walk, P A Jose and R A Felder
    Molecular Pharmacology February 1996, 49 (2) 373-378;
  • You have access
    Stimulatory regulation of the large-conductance, calcium-activated potassium channel by G proteins in bovine adrenal chromaffin cells.
    K B Walsh, S P Wilson, K J Long and S C Lemon
    Molecular Pharmacology February 1996, 49 (2) 379-386;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 49, Issue 2
1 Feb 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Read
Loading
  • Proteomic Analysis of GPCR Cell Biology
  • Phosphoproteomic Analysis of cAMP-Dependent Pathways
  • Phosphoproteomic Identification of Signaling Pathways
  • How Many G Protein-Coupled Receptors are Drug Targets?
  • Characterization of GRD and LCCH3 from Human Louse
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics